ArticleJournal of ophthalmology2014

A 2-Year, Phase IV, Multicentre, Observational Study of Ranibizumab 0.5 mg in Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice: The EPICOHORT Study.

Sergio Pagliarini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.